Cullinan Therapeutics
CGEM | NASDAQ
$9.50
-$0.78 (-7.59%)
At close: Nov 16, 2026, 4:00 PM ET
$9.51
+$0.01 (+0.11%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Cullinan Therapeutics Company Profile
Company profile explainedCompany Profile
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Nadim Ahmed | President, Chief Executive Officer & Director |
| Jacquelyn L. Sumer | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary |
| Mary Kay Fenton | Chief Financial Officer |
| Corinne Savill | Chief Business Officer |
| Jeffrey Jones | Chief Medical Officer |
| Jennifer Michaelson | Chief Scientific Officer |
| Nicholas Smith | Head of Investor Relations |
| Patrick A. Baeuerle | Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board |
| Rose Weldon | Senior Vice President of Corporate Affairs |
| Steve Andre | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2026 | 8-K | Current Report |
| Sep 24, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 8-K | Current Report |
| Sep 10, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 06, 2026 | 10-Q | Quarterly Report |
Cullinan Therapeutics
| Country | United States |
| IPO Date | Jan 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 109 |
| CEO | Nadim Ahmed |
Contact Details
One Main Street Cambridge,
Massachusetts 02142 United States
Stock Details
| Ticker Symbol | CGEM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001789972 |
| CUSIP Number | 230031106 |
| ISIN Number | US2300311063 |
| SIC Code | 2836 |
Recent News
- 2 months ago / globenewswire.comCullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
- 2 months ago / globenewswire.comCullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
- 2 months ago / seekingalpha.comCullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript
- 2 months ago / globenewswire.comCullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
- 2 months ago / gurufocus.comZipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
- 2 months ago / globenewswire.comCullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
- 3 months ago / seekingalpha.comCullinan Therapeutics: A Self-Funding Bridge To Immune Reset
- 3 months ago / benzinga.comCullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape
- 3 months ago / globenewswire.comCullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- 4 months ago / globenewswire.comCullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
Add to Watchlist
Select watchlists to add or remove CGEM